Novartis Ag (NVS) Curent Deferred Tax Liability (2018 - 2019)
Novartis Ag's (NVS) quarterly Curent Deferred Tax Liability came in at $158.0 million in Q2 2019, up 786.96% year-over-year from $17.8 million in Q2 2018, and up 786.96% quarter-over-quarter from -$23.0 million in Q2 2018.
Powered by 
Analysis
Novartis Ag (NVS) Curent Deferred Tax Liability (2018 - 2019) Analysis & Trends
Novartis Ag has disclosed Curent Deferred Tax Liability across 2 years of filings, most recently posting $158.0 million for Q2 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Curent Deferred Tax Liability (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | - |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | - |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | - |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | - |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | - |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | - |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | - |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | - |